Common over‑the‑counter meds show signs of boosting anti‑cancer immunity

- June 30, 2016

Dalhousie Medical School researchers are looking at how Zantac and Peptid AC reduce cancer growth and spread. (Nick Pearce photo)
Dalhousie Medical School researchers are looking at how Zantac and Peptid AC reduce cancer growth and spread. (Nick Pearce photo)

Dalhousie Medical School researchers are investigating how common over-the-counter drugs used for the treatment of gastrointestinal disorders might enhance the body’s immune system and ability to fight off cancer.

While a number of medications can modify immune function to enhance anti-cancer immunity, many of them can’t be used routinely because of negative side effects. But the Dalhousie team has found two everyday medications — ranitidine and famotidine — that reduce breast cancer growth and metastasis in mouse models.

“The immune system plays an important role in defending against cancer,” says Dr. Jean Marshall, professor in the Department of Microbiology & Immunology and the study’s principal investigator. “It can both reduce the incidence of initial tumour development and slow down or prevent cancer spread.”

In the general population, ranitidine and famotidine — more commonly known as Zantac and Pepcid AC — are regularly used to treat peptic ulcers and acid reflux. These non-prescription drugs, widely recognized as well tolerated and safe, are also used by cancer patients to ease chemotherapy-related nausea.

Testing anti-cancer immunity

“Because cancer patients often take these drugs to reduce chemo side effects, our team of clinical and basic scientists looked at how they impact function of the immune system in breast cancer,” says Dr. Marshall. “Our experiments have shown promising results; we found that daily treatment of ranitidine or famotidine inhibited the development and spread of breast tumours in mice.”

The next step is to test whether the drugs have a similar effect on other cancers, and if they have the same impact on the human immune system in a project recently funded by the Canadian Cancer Society.

“The outcome of our laboratory studies are exciting, warranting further investigation into their transferability to people,” says Dr. Marshall. “Rantidine and famotidine have potential to safely prevent or slow down the development of cancer by boosting the immune response. If similar effects are seen in people, the drugs could aid in effective cancer immunotherapy or cancer prevention in those at high risk of developing the disease.”

Working alongside Dr. Marshall are Dr. Lisa Barrett, viral immunologist and assistant professor in the Division of Infectious Diseases and Dr. Paola Marignani, professor in the departments of Biochemistry & Molecular Biology and Pathology.


All comments require a name and email address. You may also choose to log-in using your preferred social network or register with Disqus, the software we use for our commenting system. Join the conversation, but keep it clean, stay on the topic and be brief. Read comments policy.

comments powered by Disqus